10.10.25
7 min. Read

Revisiting E&O scoops, pricing intel, revenue finds

Issue 349

Welcome back to E&O: a paying subscribers-only weekly newsletter focused on three areas of health tech: FDA-regulated software devices, digital health as an employee benefit, and national virtual clinics.

 Exits & Outcomes Newsletter

This week's newsletter revisits some of E&O's reporting from this past year along with some updates and new commentary. Read on below for more. Was this forwarded to you? Click this link for more info

E&O Archived Post

Off-limits for now.

This archived E&O article will be included in a future paid product.

×

Flo Health’s 2025 revenue, expenses, losses and more.
7.31.26
4 min. Read
Samsung’s ACCESS Model partner. More ACCESS dropouts. Trials.
7.24.26
6 min. Read
CMS proposes to gut RPM/RTM. Thyme revenue. Swing Therapeutics acquired.
7.15.26
6 min. Read
Clinical trials snapshot: OpenEvidence, Hinge, Oura, North Shore Therapeutics, and more
7.10.26
9 min. Read
Hello Heart, Form Health pricing. Headway off the ACCESS Model list
6.26.26
3 min. Read
Oura subscription revs, rings sold, hardware margin. New ACCESS Model participants
6.05.26
7 min. Read
Six years of Oura’s financials: Revenue, profits, marketing spend and more
5.22.26
4 min. Read
ACCESS Model’s first dropout? Plus: A few new participants
5.08.26
6 min. Read
Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic
4.17.26
9 min. Read
Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board
4.10.26
13 min. Read
  • First
  • Previous
  • 1 of 43
  • Next
  • Last